Mehta, Shamir R.

Early versus delayed invasive intervention in acute coronary syndromes

Mehta, S. R., Granger, C. B., Boden, W. E., Steg, P. G., Bassand, J.-P., Faxon, D. P., Afzal, R., Chrolavicius, S., Jolly, S. S., Widimsky, P., et al. (2009) · New England Journal of Medicine

Acute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

Cited by 925

Ticagrelor in patients with stable coronary disease and diabetes

Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 365

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications

Kandzari, D. E., Townsend, R. R., Kario, K., Mahfoud, F., Weber, M. A., Schmieder, R. E., Pocock, S., Tsioufis, K., Konstantinidis, D., Choi, J., et al. (2023) · Journal of the American College of Cardiology

Blood Pressure and Hypertension StudiesCardiovascular Health and Disease Prevention

Cited by 124

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118

Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention

Angiolillo, D. J., Baber, U., Sartori, S., Briguori, C., Dangas, G., Cohen, D. J., Mehta, S. R., Gibson, C. M., Chandiramani, R., Huber, K., et al. (2020) · Journal of the American College of Cardiology

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 87

Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy

Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 44

Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction

Goyal, A., Mehta, S. R., Gerstein, H. C., Díaz, R., Afzal, R., Xavier, D., Zhu, J., Pais, P., Lisheng, L., Kazmi, K. A., et al. (2009) · American Heart Journal

Acute Myocardial Infarction ResearchHyperglycemia and glycemic control in critically ill and hospitalized patients

Cited by 35